Screener
Core Laboratories CLB Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Core Laboratories in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Core Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-198109
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Additional paid-in capital | 115,221 | 110,245 |
| Retained earnings | 171,413 | 172,662 |
| Accumulated other comprehensive income (loss) | (5,754) | (5,806) |
| Treasury stock (at cost), 918,600 and 871,489 shares at 2026 and 2025, respectively | (12,464) | (11,585) |
| Total Core Laboratories Inc. shareholders' equity | 268,886 | 265,986 |
| Non-controlling interest | 6,258 | 6,222 |
| TOTAL EQUITY | 275,144 | 272,208 |
| TOTAL LIABILITIES AND EQUITY | $587,728 | $584,010 |
Item 1. Financial Statements
FAQ
- What is Core Laboratories's total equity?
- Core Laboratories (CLB) reported total equity of $268.89M in Q1 2026.
- How has Core Laboratories's total equity changed year-over-year?
- Core Laboratories's total equity increased by 6.1% year-over-year, from $253.39M to $268.89M.
- What is the long-term trend for Core Laboratories's total equity?
- Over 3 years (2022 to 2025), Core Laboratories's total equity has grown at a 13.0% compound annual growth rate (CAGR), from $184.26M to $265.99M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Core Laboratories's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude